Tower Research Capital LLC TRC raised its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 89.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,718 shares of the biotechnology company's stock after buying an additional 3,167 shares during the quarter. Tower Research Capital LLC TRC's holdings in Repligen were worth $967,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. MetLife Investment Management LLC raised its position in shares of Repligen by 8.9% during the fourth quarter. MetLife Investment Management LLC now owns 29,774 shares of the biotechnology company's stock worth $4,286,000 after acquiring an additional 2,428 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Repligen by 28.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 580,485 shares of the biotechnology company's stock valued at $83,556,000 after buying an additional 126,913 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in shares of Repligen by 17.7% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 41,175 shares of the biotechnology company's stock worth $5,924,000 after acquiring an additional 6,200 shares in the last quarter. Champlain Investment Partners LLC grew its stake in Repligen by 8.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock valued at $222,176,000 after purchasing an additional 122,595 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Repligen during the 4th quarter valued at $792,000. Institutional investors own 97.64% of the company's stock.
Insider Buying and Selling at Repligen
In other Repligen news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is owned by corporate insiders.
Repligen Price Performance
Shares of NASDAQ:RGEN traded down $4.20 during midday trading on Tuesday, hitting $139.43. The company's stock had a trading volume of 1,990,966 shares, compared to its average volume of 717,802. The company has a market cap of $7.83 billion, a P/E ratio of -273.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52. The business's 50 day simple moving average is $139.66 and its 200 day simple moving average is $145.97. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. During the same quarter last year, the firm posted $0.28 EPS. The business's revenue was up 10.4% compared to the same quarter last year. On average, analysts forecast that Repligen Co. will post 1.72 EPS for the current year.
Analyst Ratings Changes
A number of brokerages recently weighed in on RGEN. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a report on Tuesday. JPMorgan Chase & Co. dropped their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday. Canaccord Genuity Group lowered their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Royal Bank of Canada raised their target price on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. Finally, Evercore ISI began coverage on Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective on the stock. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $174.58.
Check Out Our Latest Research Report on RGEN
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
